| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Mebeverine acid targets smooth muscle cells of the gastrointestinal tract. Unlike its parent drug mebeverine, which acts as an antispasmodic, mebeverine acid's precise molecular targets are less well-defined but are thought to involve calcium channel modulation and other non-anticholinergic pathways. As a metabolite, it does not have a primary pharmacological target per se but is used as a research tool to study smooth muscle pharmacology, gastrointestinal motility, and the metabolic conversion of mebeverine.
|
|---|---|
| ln Vitro |
In vitro studies of mebeverine acid primarily focus on its role as a metabolite rather than direct pharmacological activity. It is used in pharmacokinetic studies of mebeverine and has been shown to be effective in controlling studies in pharmaceutical dosage, enzyme inhibitor control, and elimination rates. It has also been reported to have anticoagulant activity and to inhibit drug elimination. As a secondary metabolite, it serves as a marker compound in analytical assays to monitor mebeverine exposure and metabolism.
|
| ln Vivo |
In vivo, mebeverine acid is the major circulating metabolite following oral administration of mebeverine. It is generated by hydrolysis of mebeverine in the body and serves as an important marker for oral gavage of mebeverine. While mebeverine itself exhibits antispasmodic activity in animal models of gastrointestinal motility, mebeverine acid is primarily studied as a pharmacokinetic marker rather than a pharmacologically active entity. Its presence in plasma confirms systemic exposure to the parent drug.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for mebeverine acid are not typically performed as the compound is a metabolite rather than a pharmacologically active drug. However, analytical methods such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) are used to quantify mebeverine acid in biological samples for pharmacokinetic studies. These assays involve protein precipitation, solid-phase extraction, and chromatographic separation followed by mass spectrometric detection to measure metabolite concentrations in plasma, urine, or tissue samples.
|
| Cell Assay |
Cell-based assays for mebeverine acid are not commonly reported, as the compound is primarily a metabolite marker. However, in vitro systems such as hepatocyte cultures or microsomal preparations may be used to study the metabolic conversion of mebeverine to mebeverine acid. These assays help elucidate the enzymatic pathways involved in mebeverine hydrolysis and the factors that influence its metabolism. Analytical quantification of mebeverine acid in cell culture media is performed using LC-MS/MS methods.
|
| Animal Protocol |
In vivo animal studies for mebeverine acid typically involve pharmacokinetic studies where mebeverine is administered orally to rodents or other species, and plasma samples are collected at various time points to measure the formation and elimination of mebeverine acid. The metabolite is quantified using validated bioanalytical methods to determine pharmacokinetic parameters such as Cmax, Tmax, AUC, and half-life. These studies help characterize the absorption, distribution, metabolism, and excretion of mebeverine.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of mebeverine acid are derived from studies of mebeverine metabolism. Following oral administration of mebeverine, the drug undergoes rapid and extensive hydrolysis to mebeverine acid, which is the major circulating metabolite. Mebeverine acid is considered a key circulating metabolite and an important marker of oral exposure to mebeverine. The compound has a molecular weight of 279.37 g/mol and a molecular formula of C16H25NO3. Specific PK parameters such as half-life and bioavailability are not extensively documented for the metabolite alone.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for mebeverine acid are limited, as it is a metabolite rather than a therapeutic agent. The parent drug mebeverine is generally well-tolerated at therapeutic doses, with common side effects including gastrointestinal disturbances. Mebeverine acid, as a hydrolysis product, is considered to have low toxicity. It has been shown to be an inhibitor of drug elimination and has anticoagulant properties, though these effects are primarily of pharmacological interest rather than toxicological concern. For research use only, not for therapeutic or human use.
|
| References | |
| Additional Infomation |
Mebeverine acid (CAS# 475203-77-1) is the secondary metabolite of mebeverine, an antispasmodic agent used to treat irritable bowel syndrome. It is generated by the hydrolysis of mebeverine in the body and is considered a key circulating metabolite. Mebeverine acid is a valuable marker of oral exposure to mebeverine and is used in pharmacokinetic studies to monitor drug metabolism and elimination. The compound has also been shown to have anticoagulant activity and to inhibit drug elimination. It is primarily used as a research tool in pharmaceutical and metabolic studies.
|
| Molecular Formula |
C16H25NO3
|
|---|---|
| Molecular Weight |
279.3746
|
| Exact Mass |
279.183
|
| Elemental Analysis |
C, 68.79; H, 9.02; N, 5.01; O, 17.18
|
| CAS # |
475203-77-1
|
| Related CAS # |
Mebeverine acid-d5 hydrochloride;Mebeverine acid-d5;2070015-30-2;Mebeverine-d6 hydrochloride;1329647-20-2
|
| PubChem CID |
20556914
|
| Appearance |
White to off-white solid powder
|
| Density |
1.057g/cm3
|
| Boiling Point |
428.2ºC at 760 mmHg
|
| Melting Point |
85-87ºC
|
| Flash Point |
212.7ºC
|
| Index of Refraction |
1.519
|
| LogP |
2.812
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
20
|
| Complexity |
275
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)CCCN(CC)C(C)CC1=CC=C(OC)C=C1
|
| InChi Key |
UZUWRVLVHOYTNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H25NO3/c1-4-17(11-5-6-16(18)19)13(2)12-14-7-9-15(20-3)10-8-14/h7-10,13H,4-6,11-12H2,1-3H3,(H,18,19)
|
| Chemical Name |
4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butanoic acid
|
| Synonyms |
Mebeverine Acid;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~13.33 mg/mL (~47.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5795 mL | 17.8974 mL | 35.7948 mL | |
| 5 mM | 0.7159 mL | 3.5795 mL | 7.1590 mL | |
| 10 mM | 0.3579 mL | 1.7897 mL | 3.5795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
